Community screening for hepatitis C virus infection in a low-prevalence population

BMC Public Health

Table 1 Results of HCV RNA and HCV Ag testing in anti-HCV reactive serum samples

No.	Sample ID	Age group, years	Sex of participant	Anti-HCV S/CO	Inno-LIA result	HCV Ag, fmol/L	HCV RNA	HCV viral load, IU/mL	HCV genotype
1	94	50–59	F	13.10	Pos	3391.6	Pos	820,723	1b
2	99	40–49	F	2.88	Neg	0.01	Neg	Neg	n.t.
3	335	> 70	M	12.71	Pos	4.33	Pos	594	1b
4	386	60–69	F	1.46	Ind	0	Neg	Neg	n.t.
5	409	60–69	F	1.66	Ind	0	Neg	Neg	n.t.
6	472	> 70	F	15.20	Pos	0	Neg	Neg	n.t.
7	496	> 70	M	13.66	Pos	12,121.7	Pos	2,905,138	1b
8	506	> 70	M	1.41	Ind	0	Neg	Neg	n.t.
9	544	> 70	F	1.88	Pos	0.29	Neg	Neg	n.t.
10	578	> 70	F	11.08	Pos	51.23	Pos	7819	1b
11	582	> 70	F	13.10	Pos	621.62	Pos	167,552	1b
12	704	1–14	F	0.98	Neg	0	Neg	Neg	n.t.
13	908	> 70	M	4.30	Pos	0	Neg	Neg	n.t.
14	976	60–69	M	11.60	Pos	6013.27	Pos	743,465	1b
15	983	> 70	M	10.94	Pos	502.88	Pos	83,278	1b
16	1002	50–59	F	1.59	Pos	0	Neg	Neg	n.t.
17	1074	30–39	M	12.28	Pos	7.46	Pos	17,612	3a
18	1145	40–49	M	14.54	Pos	0	Neg	Neg	n.t.
19	1444^a	20–29	F	1.01	Neg	(22.82)	Neg	Neg	n.t.
20	1517	50–59	M	14.29	Pos	0	Neg	Neg	n.t.
21	1529	50–59	M	11.51	Pos	8.92	Pos	3914	1b
22	1531	> 70	M	13.17	Pos	1906.12	Pos	385,515	1b
23	1541	50–59	M	12.14	Pos	7.54	Pos	4112	1b
24	1635	30–39	F	0.87	Neg	0	Neg	Neg	n.t.
25	1716	> 70	F	0.84	Neg	0	Neg	Neg	n.t.
26	1723	> 70	F	14.38	Pos	1496.22	Pos	320,851	1b
27	1729	> 70	F	12.04	Pos	5.08	Pos	2008	1b
28	1924	50–59	F	0.81	Neg	0	Neg	Neg	n.t.
29	2101	20–29	M	8.09	Pos	7201.39	Pos	995,879	3a
30	2018	> 70	F	13.21	Pos	2346.87	Pos	92,905	1b
31	2067	> 70	F	13.41	Pos	10,712.9	Pos	1,184,879	1b

ISSN: 1471-2458